Clinical Cancer Research · 2018 · 39 citations · 39 references
MedicineOncologyPharmacologyCancer PharmacologyMolecular OncologyOncology PharmacotherapyHematologic Malignancy PharmacotherapyPharmacodynamics Of Anticancer DrugsChronic Lymphocytic Leukemia TherapyDose Escalation TherapyJak Inhibitor TherapyJak InhibitorsJak-stat Signaling PathwayRefractory Chronic Lymphocytic LeukemiaSequential Dose EscalationTumor Response Evaluation
PURPOSE: Preclinical studies suggest SYK and JAK contribute to tumor-intrinsic and microenvironment-derived survival signals. The pharmacodynamics of cerdulatinib, a dual SYK/JAK inhibitor, and associations with tumor response were investigated. PATIENTS AND METHODS: In a phase I dose-escalation study in adults with relapsed/refractory B-cell malignancies, cerdulatinib was administered orally to sequential dose-escalation cohorts using once-daily or twice-daily schedules. The study enrolled 8 patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), 13 with follicular lymphoma, 16 with diffuse large B-cell lymphoma (DLBCL), and 6 with mantle cell lymphoma. Correlation of tumor response with pharmacodynamic markers was determined in patients with meaningful clinical responses. RESULTS: values against B-cell antigen receptor (BCR), IL2, IL4, and IL6 signaling pathways were 0.27 to 1.11 μmol/L, depending on the phosphorylation event. Significant correlations were observed between SYK and JAK pathway inhibition and tumor response. Serum inflammation markers were reduced by cerdulatinib, and several significantly correlated with tumor response. Diminished expression of CD69 and CD86 (B-cell activation markers), CD5 (negative regulator of BCR signaling), and enhanced expression of CXCR4 were observed in 2 patients with CLL, consistent with BCR and IL4 suppression and loss of proliferative capacity. CONCLUSIONS: Cerdulatinib potently and selectively inhibited SYK/JAK signaling at tolerated exposures in patients with relapsed/refractory B-cell malignancies. The extent of target inhibition in whole-blood assays and suppression of inflammation correlated with tumor response. (ClinicalTrials.gov ID:NCT01994382).
39
Dose-Response Analysis Using R
Christian Ritz, Florent Baty, J. C. Streibig et al. · PLoS ONE · 2015 · 3.7K citations · Full text
Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
R. Eric Davis, Vu N. Ngo, Georg Lenz et al. · Nature · 2010 · 1.6K citations · Full text
Medicine, Hematology, Oncology +14
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach, Richard R. Furman, Ta-Ming Liu et al. · New England Journal of Medicine · 2014 · 1.3K citations · Full text
Medicine, Oncology, Pharmacology +14
Ronald Godiska, David Chantry, Carol J. Raport et al. · The Journal of Experimental Medicine · 1997 · 488 citations · Full text